Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Abiprubart, an antibody targeting TNFRSF5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tovecimig, an antibody targeting VEGF-A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Recibokibart, an antibody targeting IL1RL2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Potravitug, an antibody targeting BK polyomavirus VP1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Etalanetug, an antibody targeting Tau.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Emugrobart, an antibody targeting ENTPD1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Roledumab, an antibody targeting RhD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Begelomab, an antibody targeting DPP4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Glenzocimab, an antibody targeting GP6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Plonmarlimab, an antibody targeting CSF2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Anbenitamab, an antibody targeting HER2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vobramitamab, an antibody targeting B7-H3.